214450 — PharmaResearch Co Share Price
0.000.00%
Last trade - 00:00- KR₩7tn
- KR₩7tn
- KR₩350bn
- 87
- 4
- 100
- 72
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 32.89 | ||
| PEG Ratio (f) | 1 | ||
| EPS Growth (f) | 49.34% | ||
| Dividend Yield (f) | 0.22% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 12.45 | ||
| Price to Tang. Book | 13.28 | ||
| Price to Free Cashflow | 75.37 | ||
| Price to Sales | 17.91 | ||
| EV to EBITDA | 43.37 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 17.96% | ||
| Return on Equity | 22.08% | ||
| Operating Margin | 36.57% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 108,745.92 | 154,082.9 | 194,758.64 | 261,010.91 | 350,115.07 | 558,936 | 729,652 | 33.08% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +100.61 | +32.86 | -4.87 | +70.08 | +16.4 | +88.3 | +36.91 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PharmaResearch Co Ltd, formerly Pharma Research Products Co Ltd, is a Korea-based company principally engaged in the manufacturing and distribution of pharmaceuticals. The Company produces and sells regenerated products such as pharmaceuticals, medical devices, and cosmetics. In addition, the Company is involved in the venture investment and real estate leasing. The Company mainly provides its products in domestic market.
Directors
- Gi Seok Kang CCE (45)
- Shin Gyu Kim CCE (55)
- Yik Su Kim VPR (51)
- Si Yin Kim DRC (59)
- Yong Seong Kim NID (33)
- Hyeon Jae Lee NID (47)
- Jae Hwi Lee NID (50)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- March 3rd, 2001
- Public Since
- July 24th, 2015
- No. of Shareholders
- 23,317
- No. of Employees
- 88
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 10,269,696
- Address
- 77-19, Gwahakdanji-ro, GANGNEUNG, 25452
- Web
- https://pharmaresearch.co.kr/
- Phone
- +82 336457640
- Auditors
- Shinhan Accounting Corporation
Upcoming Events for 214450
PharmaResearch Co Ltd Reverse Split For 214450.KQ - Ratio 0.7428-1
Similar to 214450
AbClon
Korea Exchange - KOSDAQ
ADBiotech Co
Korea Exchange - KOSDAQ
AHN-GOOK PHARMACEUTICAL Co
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
AMINOLOGICS CO
Korea Exchange - KOSDAQ
FAQ
What is the PharmaResearch Co share price?
As of Today at 13:38 UTC, shares in PharmaResearch Co are trading at KR₩684,000. This share price information is delayed by 15 minutes.
How has the PharmaResearch Co share price performed this year?
Shares in PharmaResearch Co last closed at KR₩684,000 and the price had moved by +270.93% over the past 365 days. In terms of relative price strength the PharmaResearch Co share price has outperformed the FTSE Developed Asia Pacific Index by +221.47% over the past year.
What are the analyst and broker recommendations for PharmaResearch Co?
The overall consensus recommendation for PharmaResearch Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the PharmaResearch Co dividend yield?
The PharmaResearch Co dividend yield is 0.16% based on the trailing twelve month period.
Does PharmaResearch Co pay a dividend?
Last year, PharmaResearch Co paid a total dividend of KR₩1,100, and it currently has a trailing dividend yield of 0.16%. We do not have any data on when PharmaResearch Co is to next pay dividends.
When does PharmaResearch Co next pay dividends?
We do not have data on when PharmaResearch Co is to next pay dividends. The historic dividend yield on PharmaResearch Co shares is currently 0.16%.
How do I buy PharmaResearch Co shares?
To buy shares in PharmaResearch Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of PharmaResearch Co?
As of the previous close price of KR₩684,000, shares in PharmaResearch Co had a market capitalisation of KR₩7tn.
Where are PharmaResearch Co shares listed?
Here are the trading details for PharmaResearch Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 214450
What kind of share is PharmaResearch Co?
Based on an overall assessment of its quality, value and momentum PharmaResearch Co is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a PharmaResearch Co share price forecast for 2025?
The analyst consensus target price for shares in PharmaResearch Co is KR₩806,778. That is 17.95% above the last closing price of KR₩684,000.
Analysts covering PharmaResearch Co currently have a consensus Earnings Per Share (EPS) forecast of KR₩16,901 for the next financial year.
Find out moreWhat is the trend in the PharmaResearch Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PharmaResearch Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +107.89%.
As of the last closing price of KR₩684,000, shares in PharmaResearch Co were trading +91.12% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the PharmaResearch Co PE Ratio?
The PharmaResearch Co PE ratio based on its reported earnings over the past 12 months is 32.89. The shares last closed at KR₩684,000.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of PharmaResearch Co?
PharmaResearch Co's management team is headed by:
- Gi Seok Kang - CCE
- Shin Gyu Kim - CCE
- Yik Su Kim - VPR
- Si Yin Kim - DRC
- Yong Seong Kim - NID
- Hyeon Jae Lee - NID
- Jae Hwi Lee - NID